STOCKS TELEGRAPH

Author: ST Staff

  • Cemtrex, Inc. (CETX) Stock Among Stocks Being Targeted in Resurgence of Meme Stock Phenomenon

    Cemtrex, Inc. (CETX) Stock Among Stocks Being Targeted in Resurgence of Meme Stock Phenomenon

    Cemtrex, Inc. (CETX) stock prices continue their upward trend, having ended the July 9th, 2021 trading day at USD$1.49, a 13.64% increase. Subsequent premarket fluctuations have seen the stock rise another 15.44%, bringing it up to USD$1.72.

    Revenue Reports

    CETX reported USD$9.3 million in revenue for the quarter ended March 31st 2021, representing a year-over-year decrease of 24% from the USD$12.1 million reported for the same time period of 2020. The yearly difference is largely attributable to the devastating effects resulting from the onset of the coronavirus pandemic causing shutdowns and the limiting of business operations. The Advanced Technologies segment revenues for the quarter were down 11% to USD$5.5 million, while the Industrial Services segment revenues were down 36% to USD$3.8 million.

    Net Income Improvements

    Net income for the quarter was reported at USD$2.5 million for the quarter, up significantly from the net loss of USD$1.6 million reported in the prior year quarter. This year-over-year difference is largely attributable to various income items exclusive to the 2021 quarter, including a one-time settlement agreement, as well as unrealized gains on marketable securities.

    Traded Volume Increase

    The company reported cash and cash equivalents in the amount of USD$15.6 million as of March 31st 2021, indicating a comfortable liquidity position. Nevertheless, the steep climb of volume of shares traded from the low thousands to upwards of one million over a course of days is not adequately contextualized by the company’s recent financials. Rather, the absence of any other recent news or changes in fundamentals makes the stocks recent activity highly contentious.

    Meme Stock Phenomenon

    In the absence of recent developments, it seems likely that the stock finds itself the target of the meme stock phenomenon that has been captivating the markets again as of late. Driven by retail investors, the movement has seen underdog companies being targeted for a short-term pump and dump. Companies that indicate a high short interest find their stock prices being inflated artificially with little to no reason in the coordinated short squeeze. Rife with inherent risk and volatility, the movement is not consistent or reliable. Moreover, in most cases it seems a very large correction on a very short timeframe.

    Future Outlook for CETX

    Nevertheless, armed with the fortuitous surge in equity value provides the company the exposure to capitalize on the addition opportunities it finds at its disposal. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to facilitate more organic growth over the long term.

  • SGOCO Group, Ltd. (SGOC) Stock Skyrockets as Latest Possible Target of Meme Stock Phenomenon

    SGOCO Group, Ltd. (SGOC) Stock Skyrockets as Latest Possible Target of Meme Stock Phenomenon

    SGOCO Group, Ltd. (SGOC) stock prices were up by an astounding 279.46% as of the market closing on July 9th, 2021, bringing the price per share up to USD$9.79. Subsequent premarket fluctuations have seen the stock surge by 44.02%, bringing it up to USD$14.10.

    About SGOC

    SGOC manufactures a variety of offerings, primarily phase change storage systems. Consisting of a number of businesses based in Hong Kong, SGOC focuses on VR technology, energy saving technology, mortgage lending, property investment, and a host of other growth segments across various markets. The company is continuously allocating resources towards the building of an ecosystem of sustainable growth that results in healthy gains in shareholder value.

    SGOC Financials

    The penny stock company is based in Hong Kong, with a market cap in excess of USD$1 billion. This is despite the company reporting only USD$4 million in revenue for 2020, ultimately proving itself to be unprofitable at the moment. The company also reported a liquidity position of USD$3 million, indicating a balance sheet that does not reflect its inflated market cap.

    SGOC as the Latest Meme Stock

    The company’s stock has recently skyrocketed by more than an astounding 500%. This is despite an apparent absence of significant news about the company or changes in SGOC fundamentals. Without proper contextualization, it seems possible that SGOC has become the latest target of the meme stock phenomenon that has swept through the market . This is reflected by the jump from an average 10-day trading volume of company stock in the amount of 664,000 to more than 100 million.

    SGOC Short Interest

    The meme stock phenomenon is driven by retail investors who target underdog companies in order to execute a coordinated short squeeze. Historically, meme stocks have exhibited a high short interest, which is not the case with SGOC. The company indicated a short interest level of 8%, casting doubt on its status as a meme stock. Nevertheless, data from Fintel reports a short volume ration of more than 25%. Even if the growth is not driven by the meme stock phenomenon, the limited evidence available does suggest the influence of momentum and day traders.

    Future Outlook for SGOC

    Refusing to look a gift horse in its mouth, SGOC is poised to capitalize on the expanded opportunities afforded to it in light of its recent explosion of equity value. Despite the inherent risk and volatility associated with meme stocks, the company is keen to allocate resources towards maintaining its trajectory of fortuitous success by ushering in more organic growth moving forward.

  • ZEPP Stock Rising Premarket — What Is The Reason?

    ZEPP Stock Rising Premarket — What Is The Reason?

    Shares of the cloud-based healthcare services provider with world-leading smart wearable technology, Zepp Health Corporation (ZEPP) traded at $11.14 at last check, up 6.91% on the charts in the premarket session today. As of Friday, shares of ZEPP ended the day at $10.42, up 3.99% from its previous close of $10.02.

    Stocks of ZEPP traded for a volume of 0.13 million on the day, a volume much lower than the average over the last three months of 264.92K. ZEPP stock traded between $10.08 and $10.48 in the session. ZEPP stocks rose in premarket trading today after gaining value in last session on news of a new product launch.

    What is ZEPP launching?

    As of February 25, 2021, Zepp Health changed its name from Huami Corp. (HMI) to emphasize its healthcare focus with an appealing name that transcends cultures and languages. Connecting health and technology remains ZEPP’s mission. Aware of the growing market demand for smart health devices, data analytics services for population health, and industrial medical technology, ZEPP began developing proprietary technology for data analytics, AI chips, biometric sensors, and algorithms in 2013.

    As of 2020, ZEPP is one of the largest manufacturers of smart fitness and health wearables, shipping 46 million units. ZEPP is headquartered in Hefei, China, and has a US subsidiary, Zepp Health USA, based in Cupertino, California.

    According to Zepp Health, it brand Amazfit will launch truly wireless stereo (TWS) earbuds this fall with features such as health monitoring.

    • Amazfit has been a leader in the smart wearables market for years, continually innovating and developing new products and technologies across multiple categories.
    • The new earbuds from Amazfit not only measure heart rate but also include powerful health monitoring functions.
    • This includes the ability to detect head position relative to the cervical spine, provide feedback on posture in the app, and play rhythms when the user hasn’t moved for an extended period of time.
    • In addition to analyzing volume and listening habits, these earbuds help protect users’ hearing.
    • The new Amazfit earbuds will not only provide cutting-edge audio but also be a companion for health and fitness tracking and will block out unwanted noise.

    Global shipments of ZEPP are on the rise:

    Worldwide Quarterly Wearable Device Tracker, published by International Data Corporation (IDC), recently unveiled that for the first time Amazfit and Zepp-branded products were among the top four global shipment units for the first quarter of 2021. According to IDC data for the first quarter of 2021, Zepp Health (ZEPP) has consolidated its market leadership positions in a number of countries, particularly in Brazil, Spain, and Russia where its own brand products had market shares of 40.9%, 23.5%, and 28.9% respectively.

  • Premarket Trading: What Caused JUPW Stock To Fall By 9%?

    Premarket Trading: What Caused JUPW Stock To Fall By 9%?

    Jupiter Wellness Inc. (JUPW) shares dropped -9.46% at $4.02 at the last check during the premarket session today. During the weekend trading session, Jupiter Wellness stock gained 12.98% to $4.44 per share. JUPW stock recorded an average of 0.98 million shares traded on the day, above the average volume over the past 50 days of 0.14 million shares.

    During the last five days, JUPW shares decreased by -0.67%, and over the past month, they declined by -3.27%. Over the past three months, JUPW’s stock price has fallen by -11.02%. As a result of entering into an exclusive licensing agreement, JUPW stock gained ground in the past session but is losing it today.

    In what product did JUPW obtain a license?

    In addition to developing skin care products, Jupiter Wellness also offers skincare treatments. JUPW’s product pipeline includes the endocannabinoid system as part of its enhanced skin care therapeutics, which target eczema, burns, herpes cold sores, and skin cancer indications. JUPW generates revenue from a growing line of privately-held skincare and wellness products, including CaniSun sunscreen. JUPW’s CBDCaring.com website sells other wellness brands.

    In an exclusive license agreement announced on Friday, Jupiter Wellness is licensed to market Photocil, a novel topical cream that combats Psoriasis, Vitiligo and Atopic Dermatitis.

    • A license agreement signed between JUPW and Applied Biology (“AB”) makes JUPW the exclusive licensee for Photocil in the U.S.
    • In the Agreement, JUPW has access to the copyrights, patents, technology, know-how, trademarks, trade secrets, trademark applications, and trade names of AB related to the use of Photocil by JUPW.
    • The rights granted to JUPW to use the intellectual property exclusively entitle the company to manufacture, market, advertise, promote and distribute Photocil for the treatment of skin conditions, including psoriasis and vitiligo.
    • In Europe, Asia, and Middle East, Photocil is already available under the names Presilux and MediSun.
    • JUPW is expanding and complementing its strategy for treating skin diseases such as Eczema, Psoriasis and Vitiligo through the licensing of Photocil.
    • An atopic dermatitis clinical trial involving JW-100, JUPW’s novel topical formulation containing CBD and Aspartame, showed significant reduction in ISGA scores after two weeks in 50% of patients.
    • When skin is exposed to direct sunlight, Photocil cream serves as a barrier against non-therapeutic radiation.
    • As a result of Photocil cream’s barrier, daytime self-treatment from the sun’s therapeutic (beneficial) UV radiation, commonly referred to as phototherapy, can be achieved safely and effectively.
    • Photocil cream replaced the UV photo lamp, which was utilized for phototherapy prior to the advent of Photocil cream.

    Jupiter Wellness’ plan for Photocil:

    Licenses for Photocil will allow Jupiter Wellness (JUPW) to offer additional treatment options to patients suffering from skin ailments or seeking AM/PM or combination therapies. Upon registration and FDA approval, JUPW plans to market Photocil immediately.

  • TESS Stock Dropped Nearly 6% Premarket: Why?

    TESS Stock Dropped Nearly 6% Premarket: Why?

    Shares of leading value-added distributor and solutions provider for the wireless industry, TESSCO Technologies Incorporated (TESS) were down -5.75% to $6.72 in premarket trading at last check. TESSCO stock closed the last trading session at $7.13, rising by 5.16 percent or $0.35. During regular trading, shares of TESS fluctuated between $6.13 and $7.30.

    TESS stock traded 0.44 million shares on the day, exceeding the company’s 50-day daily volume of 0.12 million and exceeding its Year to Date volume of 76255.0. TESS stock ran in regular session after posting preliminary select financial results but fled premarket today.

    How are TESS’s preliminary select financial results?

    As a provider of wireless infrastructure technologies, TESSCO specializes in distributing, manufacturing, and providing solutions to commercial clients. In its more than 30 years of existence, TESS has consistently provided industry-leading products, knowledge, and services.

    With more than 65,000 products for mobile communications, Wi-Fi, Internet of Things (“IoT”), wireless backhaul, and more, TESS represents 250 of the industry’s top manufacturers. Wireless industry experts at TESS guarantee outstanding customer experiences, expert knowledge, and complete end-to-end solutions.

    Earlier this week, TESSCO announced preliminaries for its first quarter of the fiscal year 2022, which ended June 27, 2021.

    • According to TESS, total revenues will reach approximately $105 million, representing a composite growth rate of 9%.
    • At TESS, sales bookings increased by 37% year over year during the first quarter, with better results in both markets.
    • The current fiscal year is TESS’s first one since its retail business was sold, and the company is now showing signs of recovering from the pandemic across its markets despite some disruptions in global supply chains.
    • As the vast majority of its staff return to work after working remotely for such a long time, TESS believes that now is an appropriate time to provide a high-level overview of its expected financial outcome for the first quarter, as well as certain financial expectations for its full fiscal year 2022.
    • Due to the reduction in the effects of the pandemic, TESS reported higher sales bookings in the second half of fiscal 2021 than in the first half.
    • Due to supply chain challenges, TESS experienced a growing backlog of bookings that were not converted into shipments.
    • The trend continued into TESS’ first quarter of fiscal year 2022.

    TESS’ expectations:

    The first quarter of 2022 saw TESSCO (TESS) experiencing robust growth in both the Carrier and the VAR and integrator markets. In total, TESS expects to report revenues of approximately $105 million for the first quarter, representing a growth of 9% over the same period last year. TESS expects revenue growth of approximately 19% in its Carrier market, and approximately 2% in its VAR and Integrator market.

  • How Has The Celldex (CLDX) Stock Appreciated 35% In Extended Trading?

    How Has The Celldex (CLDX) Stock Appreciated 35% In Extended Trading?

    At last check on Friday, Celldex Therapeutics Inc. (CLDX) shares were up 35.39% to $43.88 after hours. CLDX stock closed Friday’s trading session at $32.41 up 4.41%. Volume on CLDX stock rose to 0.61 million shares, more than the average daily volume of 0.57 million shares over the past 50 days.

    In the last 12 months, shares of CLDX have risen 161.16%, but have moved down -5.87% in the past week. CLDX stock gained 56.49% in the last three months, while it lost 85.31% in the last six months. The current market value of CLDX is $1.23 billion, and the stock has 39.61 million outstanding shares. Following the presentation of positive results from one of its studies at EAACI 2021, CLDX stock shot up in extended trade.

    What did CLDX present?

    Celldex is a cutting-edge biotechnology company focused on developing bispecific and monoclonal antibodies to treat devastating diseases currently for which no effective treatment exists. With its antibody-based therapeutics, CLDX aims to treat inflammatory diseases and many forms of cancer by directly altering human immune systems and/or critical pathways.

    On Friday, Celldex announced updated results from its ongoing Phase 1b clinical study of CDX-0159.

    • It was conducted in patients with antihistamine-refractory cold urticaria and symptomatic dermographism, which are chronic inducible urticaria conditions.
    • Diseases of this type can have significant effects on patients, as they are frequently severe and debilitating.
    • CLDX’s humanized monoclonal antibody, CDX-0159, specifically binds and inhibits the tyrosine kinase KIT receptor with high specificity.
    • After receiving a single full dose of CDX-0159, all 19/19 or 100% patients who received a provocation test showed a clinical response.
    • CLDX’s study showed that 18 out of 19 patients or 95% had a complete response and only one out of 19 showed a marked partial response.
    • In addition, CLDX observed that responses were rapid, profound, and durable, as well as correlated with a depletion of mast cells in the skin.
    • The CDX-0159 showed a generally favorable reaction rate at CLDX’s study.
    • During the 2021 Annual Conference of the European Academy of Allergy and Clinical Immunology (EAACI) , Dr. Marcus Maurer, Professor of Dermatology and Allergy at Charité – Universitätsmedizin, presented this study.

    What CLDX plans to do next:

    CLDX achieved 95% success rate when there are no previous documented cases in this patient population where such high rates of complete response and rapid onset were obtained. The impressive early data from CLDX study indicate that CDX-0159 can safely affect other mast cell-related diseases, which is an important aspect for the future application of this therapy. Celldex (CLDX) is encouraged by these preliminary findings, and has set its sights on expanding the CDX-0159 program into prurigo nodularis later this year, as well as other indications involving mast cells in the future.

  • On What Basis Did Chiasma (CHMA) Stock Rise 7% In After Hours Session?

    On What Basis Did Chiasma (CHMA) Stock Rise 7% In After Hours Session?

    On the last check on Friday, Chiasma Inc. (CHMA) was trading at $4.79, up 6.92%. Chiasma stock finished the last trading session at $4.48, up 2.99%. CHMA stock price ranged from $4.30 to $4.49 during the session. CHMA traded 0.63 million shares on the day as compared to its 100-day average daily volume of 2.57 million.

    Within the last five days, CHMA stock has dropped by -5.29%, while in the past month it has risen 7.69%. With the CHMA stock rising in the absence of recent news, we can then look to recent developments to provide a more comprehensive understanding of CHMA.

    Recently, how have things been at CHMA?

    Chiasma is a biopharmaceutical company that develops and commercializes oral treatments for rare and serious chronic diseases, including most cancers, to enhance the lives of patients with a number of challenges associated with existing treatments. CHMA aims to develop oral medications by utilizing its Transient Permeability Enhancer (TPE) technology platform.

    The FDA approved the CHMA drug, MYCAPSSA, in June 2020 for the treatment of acromegaly patients who have responded to or tolerated treatment with octreotide or lanreotide. It is somatostatin analog that is available for sale in the U.S., which is the first and only oral somatostatin analog approved by the FDA. CHMA has its headquarters in Needham, Massachusetts, as well as an Israeli subsidiary. Chiasma trademarks include MYCAPSSA, TPE, and CHIASMA.

    A Marketing Authorization Application (MAA) has been submitted to the European Medicines Agency (EMA) seeking approval of MYCAPSSA (oral octreotide capsules) as a maintenance therapy for adults with acromegaly.

    • During CHMA’s MPOWERED trial, which lasted 15 months, participants were randomized, open-label, active-controlled and placed in a global setting.
    • MYCAPSSA was compared to long-acting somatostatin analogs (SSAs) in this non-inferiority trial by CHMA.
    • CHMA enrolled 146 adult acromegaly patients, of which 92 patients were successful after six months on MYCAPSSA.
    • These patients were then randomized into 9 months of controlled treatment (RCT) on either MYCAPSSA or their previous injectable therapy.
    • Its primary outcome was the nine-month average time-weighted measurement of a serum IGF-1 level that was 1.3 times the upper limit of normal.
    • As previously reported by CHMA, MPOWERED demonstrated non-inferiority to long-acting SSA injectables.
    • MyCAPSSA is the first and only oral treatment for acromegaly approved by the Food and Drug Administration (FDA) and is approved for use in patients who have experienced response and tolerated treatment with injectable octreotide or lanreotide.

    What prompted CHMA to submit an MAA?

    Chiasma (CHMA) was able to file its MAA because of positive Phase 3 results in MPOWERED. CHMA submitted its MAA as intended to the EMA, a milestone in CHMA’s efforts to bring MYCAPSSA to patients with acromegaly outside of the US.

  • Cohen & Company, Inc. (COHN) Stock Trends Lower After Period of Heightened Trade Activity Cools Off

    Cohen & Company, Inc. (COHN) Stock Trends Lower After Period of Heightened Trade Activity Cools Off

    Cohen & Company, Inc. (COHN) stock prices were down by a marginal 6.65% some time after market trading commenced on July 9th, 2021, bringing the price per share down to USD$25.25 early on in the trading day.

    Net Income

    Net income for the first quarter of 2021, ended March 31st, 2021, came out to USD$9.4 million, representing a net income of USD$6.98 per diluted share. This is comparable to the USD$3.1 million net loss reported for the prior-year quarter, representing a net loss of USD$7.64 per diluted share.

    Revenue Reports

    Revenues for the quarter were up USD$36.3 million as compared to the prior quarter, with the year-over-year increase being largely attributable to an increase of USD$1.1 million in net trading revenue. A USD$1.7 million decrease in asset management revenue also contributed to the difference, with the decrease being related to an incentive allocation earned by the company’s SPAC funds manager in the prior quarter.

    Dissecting Comparative Revenue Reports

    Further compounding the difference was an increase of USD$0.1 million in new issue and advisory revenue associated with insurance asset origination in Europe and the U.S. Most significantly, the company reported USD$36.8 million in the increase in principal transactions related to the closing of COHN’s second sponsored SPAC in February 2021. The move generated USD$73.2 million of principal transactions revenue for Q1 2021, partially offset by a reduction of USD$37.8 million in principal revenue generated from the closing of the company’s first sponsored insurance SPAC in the previous quarter.

    Liquidity Position

    The company reported USD$154.7 million in total equity as of March 31st, 2021, up from the USD$101.4 million reported as of December 31st, 2020. the non-convertible non-controlling interest component of total equity was USD$45 million as of March 31st, 2021, while the company reported USD$27.8 million as of December 31st, 2020. Accordingly, the total equity excluding the non-convertible, non-controlling interest component was USD$109.7 million as of March 31st, 2021, a USD$36.1 million increase from the USD$73.6 million reported as of December 31st, 2020.

    Contextualizing COHN and its Future Outlook

    With promising financials reported earlier in the quarter, COHN stocks have seen trading volume surge recently, positively impacting the company’s equity value. With the activity not being volatile enough to attribute to the meme stock phenomenon, the company seems to have caught the eyes of day traders who are capitalizing on the snowballing upward trajectory of the stock price. Long term investors are hopeful that the company will be able to leverage its resources to usher in more organic growth over the long term.

  • Why is AAVE coin moving upwards?

    Why is AAVE coin moving upwards?

    Aave (AAVE) has been one of the best performing cryptocurrencies in the past week with a gain of 32%. The cryptocurrency has been trending upwards since the end of June all thanks to increasing interest in decentralized finance. At the time of writing, Aave stands at a price level of $299. The cryptocurrency moved upwards by 6% in the daily timeframe while the trading volume increased by nearly 30%.

    The market sentiment for Aave is bullish. Out pf the total twenty-six technical indicators, eleven are giving out a signal of buy with nine standing at a neutral position and six indicators signaling a sell position. The oscillators are neutral while the moving averages suggest a strong uptrend.

    DeFi space has been one of the top sectors in terms of performance. Although the bearish divergence of the market resulted in investors shying away from DeFi space along with other sectors, a comeback is being observed. In the past week, the DeFi sector has increased by $15 billion while the market capitalization skirted close to $80 billion. The DeFi space is one of the most lucrative sectors of the blockchain industry with good potential. Cryptocurrencies like Aave and Compound have contributed significantly to its growth.

    The development team of Aave has a lot in store for the DeFi lending protocol. The team revealed the news of a Pro version of the network to be launched soon in a Webinar held last week. Following the webinar, attendees received a follow-up email with more details of the permissioned version. Aave Pro is targeted towards institutional investors and will incorporate V2 smart contracts. The pro version has been cited to be a result of increasing interest in the project of institutional investors. The launch of Aave pro is scheduled for July and has helped turned the market sentiment for Aave bullish.

    Is Aave a good long-term investment?

    The DeFi sector, in general, has a lot of potential – which appears to be only increasing with time. The technical for the cryptocurrency indicate towards more bullish momentum. The price forecasts for Aave in the long run are also bullish. According to Wallet Investor, Aave price level will be close to $800 in a year’s time while it is expected to be trading at $3,086 in five years’ time. Per the estimates of Digital Coin Price, Aave crypto will end the year with a price level of $425 while the price in 2028 is expected to be $1,329.

  • Stamps.com, Inc. (STMP) Stock Skyrockets Following Announcement of Acquisition by Thoma Bravo

    Stamps.com, Inc. (STMP) Stock Skyrockets Following Announcement of Acquisition by Thoma Bravo

    Stamps.com, Inc. (STMP) stock prices were up by a marginal 0.36%, bringing it up to USD$197.72 as of the market closing on July 8th, 2021. Premarket fluctuations saw the stock skyrocket by 63.55%, bringing it up to USD$323.38.

    Merger with Thoma Bravo

    July 9th, 2021 saw the company announce that it had entered into a definitive agreement that would see it being acquired by the leading software investment firm, Thoma Bravo. As per the agreement, the transaction will be conducted entirely in cash, with STMP being valued at roughly USD$6.6 billion.

    Details of the Merger

    Stockholders of the company will receive USD$330 per share in cash, which represents an impressive 67% premium over the company’s closing share price on July 8th 2021. The premium represents a 71% increase from the company’s volume-weighted average closing share price over the three-month period ended July 8th, 2021.

    Expanded Scope of STMP

    Upon the closing of the transaction, STMP will become a private company with the added resources and increased flexibility to ensure the continued provision of best-in-class global e-commerce technology solutions. Furthermore, the company will benefit from the operating capabilities, capital support, and deep sector expertise of its partner.

    Go-Shop Option

    The agreement includes a 40-day period that will expire on August 18th, 2021, wherein the company is allowed to actively initiate, solicit, and consider alternative acquisition proposals from third parties. Should this be exercised, the Board will have the right to void the merger agreement in favor of entering a superior proposal. The transaction is expected to close in the third quarter of 2021, pending customary closing conditions, including, but not limited to stockholder approval and the receipt of regulatory approvals.

    Benefits of the Merger

    With the expanded financial and operational resources generated from the merger agreement, the company can continue capitalizing on more and more growth opportunities. STMP hopes to maximize market penetration in the e-commerce shipping market, while consolidating its position as a leader in global multi-carrier e-commerce shipping software. This position of leadership is evidenced by the company being the first of its kind to introduce online postage, as well as its having been an early innovator in e-commerce shipping software.

    Future Outlook for STMP

    Armed with the expansive potential of its pending merger with Thoma Bravo, STMP is poised to capitalize on the opportunities afforded to it in light of the combined pool of resources available to it. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to sustain the successful trajectory of growth over the long term.